Literature DB >> 6786636

Labetalol-induced toxic myopathy.

A Teicher, T Rosenthal, E Kissin, I Sarova.   

Abstract

Labetalol has been successful in treating hypertension, and few side effects have been reported, although there have been cases of muscle pain during treatment. A patient with essential hypertension treated with labetalol 600 mg daily complained of muscle pains, particularly in the legs. No neurological abnormality was found, but the activity of muscle enzymes in the blood was high. Findings on electromyography were compatible with myositis and electron microscopical findings suggested toxic myopathy. Labetalol was stopped for 10 days, and the muscle pain disappeared and enzyme activity returned to normal. When labetalol was restarted the pain returned and enzyme activities rose. Myopathy should be considered in patients experiencing muscle pain after treatment with labetalol.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6786636      PMCID: PMC1506441          DOI: 10.1136/bmj.282.6279.1824

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  5 in total

1.  Experimental chloroquine myopathy.

Authors:  R D Macdonald; A G Engel
Journal:  J Neuropathol Exp Neurol       Date:  1970-07       Impact factor: 3.685

2.  Anti-hypertensive action, time of onset and effects on carbohydrate metabolism of labetalol.

Authors:  O Andersson; G Berglund; L Hansson
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

3.  Treatment of hypertension with labetalol.

Authors:  P Bolli; H J Waal-Manning; F O Simpson; H M Seeman
Journal:  N Z Med J       Date:  1977-12-28

4.  Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors.

Authors:  J B Farmer; I Kennedy; G P Levy; R J Marshall
Journal:  Br J Pharmacol       Date:  1972-08       Impact factor: 8.739

5.  A study of labetalol in patients of European, West Indian and West African origin.

Authors:  K Jennings; V Parsons
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

  5 in total
  11 in total

1.  Evaluation of antihypertensive drugs in combination with enzyme replacement therapy in mice with Pompe disease.

Authors:  Sang-Oh Han; Alexina C Haynes; Songtao Li; Dennis M Abraham; Priya S Kishnani; Richard Steet; Dwight D Koeberl
Journal:  Mol Genet Metab       Date:  2019-10-17       Impact factor: 4.797

2.  Rapid reduction of blood pressure with acute oral labetalol.

Authors:  A B Davies; V Bala Subramanian; B Gould; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

Review 3.  Adverse effects of drugs on muscle.

Authors:  F L Mastaglia
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

Review 4.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 5.  Toxic myopathies.

Authors:  Mamatha Pasnoor; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

6.  Selective beta-adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects.

Authors:  B Tomlinson; J M Cruickshank; Y Hayes; J C Renondin; J B Lui; B R Graham; A Jones; A D Lewis; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

Review 7.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 8.  Pharmacology of combined alpha-beta-blockade. I.

Authors:  W J Louis; J J McNeil; O H Drummer
Journal:  Drugs       Date:  1984       Impact factor: 9.546

9.  Bucindolol: effects on blood pressure, airways resistance and serum creatine phosphokinase.

Authors:  J S Gill; D G Beevers
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 10.  Drug-induced neurological disorders.

Authors:  R J Lane; P A Routledge
Journal:  Drugs       Date:  1983-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.